. 2021 Jun 22;13:577–591. doi: 10.2147/JEP.S262344

Table 3.

Approved Agents for the Treatment of PTCLs

Agent	Target	Phase	N	ORR (%)	Median DOR (Months)	Median PFS (Months)	Median OS (Months)	AEs Grade ≥3
Agent	Target	Phase	N	CR (%)	Median DOR (Months)	Median PFS (Months)	Median OS (Months)	AEs Grade ≥3
Pralatrexate³⁹	Antifolate	II (PROPEL)	111	29	10.1	3.5	14.5	Thrombocytopenia (32%), mucositis (22%), neutropenia (22%), anemia (18%)
Pralatrexate³⁹	Antifolate	II (PROPEL)	111	11	10.1	3.5	14.5
Romidepsin⁴³	HDAC-1 inhibitor	II	130	25	17	4	11.3	Thrombocytopenia (24%), neutropenia (20%), infections (19%)
Romidepsin⁴³	HDAC-1 inhibitor	II	130	15	17	4	11.3	Thrombocytopenia (24%), neutropenia (20%), infections (19%)
Belinostat⁴⁴	Pan-HDAC inhibitor	II (BELIEF)	129	25.8	13.6	1.6	7.9	Anemia (10.8%), thrombocytopenia (7%), neutropenia (6.2%), dyspnea (6.2%)
Belinostat⁴⁴	Pan-HDAC inhibitor	II (BELIEF)	129	10.8	13.6	1.6	7.9
Brentuximab vedotin⁴⁶ ALCL	CD30 antibody	II	58	86	12.6	13.3	Not reached	Neutropenia (21%), thrombocytopenia (14%), peripheral sensory neuropathy (12%)
Brentuximab vedotin⁴⁶ ALCL	CD30 antibody	II	58	57	12.6	13.3	Not reached
Chidamide⁴⁵	HDAC1/2 inhibitor	II (Chinese)	79	28	9.9	2.1	21.4	Thrombocytopenia (22%), leucopenia (13%), neutropenia (11%)
Chidamide⁴⁵	HDAC1/2 inhibitor	II (Chinese)	79	14	9.9	2.1	21.4	Thrombocytopenia (22%), leucopenia (13%), neutropenia (11%)
Mogamulizumab⁴⁷	Anti-CCR4 Antibody	II (Japanese)	37	35	Not reported	3.0	Not reached	Lymphocytopenia (73%), neutropenia (19%), leukocytopenia (14%)
Mogamulizumab⁴⁷	Anti-CCR4 Antibody	II (Japanese)	37	14	Not reported	3.0	Not reached

Abbreviations: ORR, objective response rate; CR, complete response; DOR, duration of response; PFS, progression-free survival; OS, overall survival; AE, adverse events; HDAC, histone deacetylase; CCR4, chemokine receptor 4.